Abstract
PurposeThe purpose of this document is to provide guidance for the use of next-generation sequencing (NGS, also known as massively parallel sequencing or MPS) in Canadian clinical genetic laboratories for detection of genetic variants in genomic DNA and mitochondrial DNA for inherited disorders, as well as somatic variants in tumour DNA for acquired cancers. They are intended for Canadian clinical laboratories engaged in developing, validating and using NGS methods.Methods of statement developmentThe document was drafted by the Canadian College of Medical Geneticists (CCMG) Ad Hoc Working Group on NGS Guidelines to make recommendations relevant to NGS. The statement was circulated for comment to the CCMG Laboratory Practice and Clinical Practice committees, and to the CCMG membership. Following incorporation of feedback, the document was approved by the CCMG Board of Directors.DisclaimerThe CCMG is a Canadian organisation responsible for certifying medical geneticists and clinical laboratory geneticists, and for establishing professional and ethical standards for clinical genetics services in Canada. The current CCMG Practice Guidelines were developed as a resource for clinical laboratories in Canada and should not be considered to be inclusive of all information laboratories should consider in the validation and use of NGS for a clinical laboratory service.
Subject
Genetics (clinical),Genetics
Reference29 articles.
1. ACMG clinical laboratory standards for next-generation sequencing
2. Guidelines for diagnostic next-generation sequencing
3. Canada H . Health care system legislation and guidelines—Canada.ca, 2005. Available: https://www.canada.ca/en/health-canada/services/health-care-system/legislation-guidelines.html [Accessed 19 Feb 2018].
4. ISO EN 15189: 2012. Medical laboratories—requirements for quality and competence, Geneva: ISO; 2012.
5. Coming of age: ten years of next-generation sequencing technologies
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献